A mouse watched YouTube. Then scientists mapped a tiny piece of its brain.
A mouse watched YouTube. Then scientists mapped a tiny piece of its brain. Scientists say the map of a speck of a mouse's brain could be as transformative as the Human Genome Project. Here's what to know.
Show Caption
Hide Caption
Dire wolves extinct for 13,000 years recreated from ancient DNA
Colossal, a Texas-based biotech company, revealed that it successfully recreated extinct dire wolves.
Scientists created the largest functional map of a brain to date using a piece of a mouse's brain.
The map details the wiring that connects neurons, offering insight into brain function and organization.
Researchers believe this work could eventually lead to treatments for brain disorders like Alzheimer's, Parkinson's and schizophrenia.
Scientists have achieved a feat once believed impossible, constructing the largest functional map of a brain to date, which they believe could eventually lead to the discovery of medications for hard-to-treat brain disorders like Alzheimer's and Parkinson's disease.
Using a piece of a mouse's brain no larger than a grain of sand, scientists from across three institutions created a detailed diagram of the wiring that connects neurons as they send messages through the brain.
The project, called Machine Intelligence from Cortical Networks (MICrONS), offers unprecedented insight into the brain's function and organization that could help unlock the secrets of intelligence.
David Markowitz, a scientist who helped coordinate the project, said the data, published April 9 in the journal Nature marks 'a watershed moment for neuroscience, comparable to the Human Genome Project in their transformative potential.'
If you give a mouse YouTube
In the study, scientists looked at a small piece of the mouse's brain called the neocortex, which receives and processes visual information. It's the newest part of the brain in terms of evolution, and differentiates the brains of mammals from other animals, according to researchers.
A team of researchers at Baylor College of Medicine in Houston started by recording brain activity in a portion of the mouse's visual cortex roughly the size of a grain of salt while it watched a series of YouTube clips and movies.
Scientists at the Allen Institute, a research center in Seattle, then sliced that piece of the mouse's brain into more than 25,000 layers, each a tiny fraction of the width of a human hair, and took high resolution photos of the slices through microscopes. The material was sent to a team at Princeton University, in New Jersey, which used artificial intelligence to reconstruct the pieces in 3D.
Other scientists compared their approach to understanding a car's combustion engine.
'Just as an engine is composed of pistons, cylinders and a fuel system, the brain consists of neurons and synapses – the tiny, specialized connections at which neurons communicate,' two Harvard researchers wrote in a companion piece to the Nature article.
The data set from the research contains 84,000 neurons, 500 million synapses and neuronal wiring that could extend the length of New York's Central Park nearly one and a half times, molecular biologists Mariela Petkova and Gregor Schuhknecht wrote.
Findings from the studies have led to discoveries of new cell types, characteristics and ways to classify cells, researchers said. The achievement also puts scientists closer to their larger goal of mapping the wiring of the entire brain of a mouse.
'Inside that tiny speck is an entire architecture like an exquisite forest,' Clay Reid, a senior investigator who helped pioneer this area of study, said in a statement. 'It has all sorts of rules of connections that we knew from various parts of neuroscience, and within the reconstruction itself, we can test the old theories and hope to find new things that no one has ever seen before.'
Why it matters
Researchers view wiring diagrams as a foundational step that scientists can build on and, eventually, potentially use to find treatments for brain conditions like Alzheimer's, Parkinson's and schizophrenia.
They compare the studies to the Human Genome Project, which created the first complete map of the DNA in every human cell. The Human Genome Project has led to profound advances in drug discovery, treatments and disease screenings and helped pave the way for revolutionary gene therapies to treat certain diseases, including some cancers.
With a functional map of the brain, researchers say they now have the ability to understand the brain's form and function and have opened up new pathways to study intelligence.
Nuno da Costa, an associate investigator at the Allen Institute, described the data they collected as a 'kind of Google map' of the piece of the visual cortex.
'If you have a broken radio and you have the circuit diagram, you'll be in a better position to fix it,' he said in a statement. 'In the future, we can use this to compare the brain wiring in a healthy mouse to the brain wiring in a model of disease.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
Yahoo
8 hours ago
- Yahoo
Museum in Seymour opens new wing with annual festival
SEYMOUR (KFDX/KJTL)— The Whiteside Museum of Natural History is celebrating the opening of a new museum expansion through their annual Permian Fest. This year's Permian Fest kicked off with the grand opening of the museum's new wing, which doubles the size of the original building. So, while families and prehistory enthusiasts could come and check out guest lectures and shop outside the museum, the views inside the building's new wing were another sight to behold. While Permian Fest is usually a big driver for fundraising on its own, the new wing is generating a lot of enthusiasm for the museum's future from the guests and museum staff, like assistant director Holly Simon. 'Locals here don't get to experience going to big museums, and our museum was definitely very popular with the local community,' Simon said. 'But now that we have a giant Ceratosaurus skeleton and a big mammoth skeleton, it's really cool that we get to bring that big city museum experience to the locals.' The expansion adds a total of 9,000 square feet to the museum's footprint, and the new space allows for reorganizations of old exhibits and the expansion of others. The new Bakker Dinosaur Hall and the Sundell Mammal Hall are two such examples. The fossil preparation lab also got a major expansion. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
8 hours ago
- Yahoo
2025 Cattle Baron's Ball raises money for cancer research in Tyler
TYLER, Texas (KETK) – The annual Cattle Baron's Ball was held at the Texas Rose Horse Park on Saturday as a way to benefit the American Cancer Society's work to end cancer. UT Tyler gets $441K grant to develop cancer-targeting nanotechnology The 'toe-tapping, knee-slapping' event featured food, drinks, dancing, an auction and raffle tickets, all supporting the American Cancer Society. 'The American Cancer Society is working to end cancer as we know it, for everyone. We are the largest private, not-for-profit funder of cancer research in the United States, investing more than $4 billion since 1946,' the American Cancer Society said. 'Thanks in part to our contributions, more than 1.5 million lives have been saved in the US in the past two decades. Now, that is a reason to celebrate!' According to the American Cancer Society's website, this year's mission with the Cattle Baron's Ball is to raise money for breast cancer research and to help provide access to cancer care across Texas by providing grants to cover transportation and lodging costs in Texas health systems. To learn more, visit the Cattle Baron's Ball online. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
